News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC Infant Lung Drug Faces U.S. Delay
December 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Nov 28 (Reuters) - AstraZeneca Plc faces a delay in getting a new infant lung drug from its recently acquired MedImmune biotech unit to market in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Drug pricing
TrumpRx Website Set To Launch Thursday Evening After Delay
February 5, 2026
·
1 min read
·
Dan Samorodnitsky
Job Trends
3 Top Challenges Facing Regulatory Professionals Right Now
February 5, 2026
·
4 min read
·
Angela Gabriel
FDA
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says
February 4, 2026
·
2 min read
·
Tristan Manalac
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
·
1 min read
·
Heather McKenzie
